iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/36139989/
The Role of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infections: A Review of the Current Literature and Paradigm Shift after 2021 - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 7;11(9):1211.
doi: 10.3390/antibiotics11091211.

The Role of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infections: A Review of the Current Literature and Paradigm Shift after 2021

Melanie L Hyte  1 , Lee J Arphai  2 , Charles J Vaughn  3 , Spencer H Durham  3
Affiliations
Review

The Role of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infections: A Review of the Current Literature and Paradigm Shift after 2021

Melanie L Hyte et al. Antibiotics (Basel). .

Abstract

Clostridioides difficile infections (CDIs), and particularly recurrent infections, cause a significant burden on the health-care system. Bezlotoxumab is a new agent for the prevention of recurrent CDIs that has shown strong efficacy and high tolerability in clinical trials. The purpose of this review is to evaluate the published literature for bezlotoxumab, with a focus on literature published since the release of the 2021 focused update to the CDI treatment guidelines. A Medline/PubMed search for "bezlotoxumab" was conducted, resulting in 152 articles. Seventeen studies are included in this review, after excluding non-English-language papers, phase I and II trials, and review articles. Studies published since the 2021 focused update support the recommendations in those guidelines. Furthermore, real-world studies have shown similar results to larger clinical trials. Those with more risk factors for recurrent CDI appear to benefit most from bezlotoxumab. Currently, there are no data to support the use of bezlotoxumab outside current guideline recommendations, but future trials may build on the data seen in real-world studies to further elucidate the place in therapy for bezlotoxumab.

Keywords: CDI; Clostridioides difficile; bezlotoxumab; pharmacotherapy; recurrence.

PubMed Disclaimer

Conflict of interest statement

M.L.H is a speaker for Promotional Programs of Paratek Pharmaceuticals. S.H.D. has participated in advisory boards for Thera Technologies, but the relationship has now been mitigated. The other authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Guh A.Y., Mu Y., Winston L.G., Johnston H., Olson D., Farley M.M., Wilson L.E., Holzbauer S.M., Phipps E.C., Dumyati G.K., et al. Emerging Infections Program Clostridioides difficile Infection Working Group. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N. Engl. J. Med. 2020;382:1320–1330. doi: 10.1056/NEJMoa1910215. - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention Antibiotic Resistance Threats in the United States 2019. [(accessed on 22 July 2022)];2019 December; Available online: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-re....
    1. Heinrich K., Harnett J., Vietri J., Chambers R., Yu H., Zilberberg M. Impaired quality of life, work, and activities among adults with Clostridium difficile infection: A multinational survey. Dig. Dis. Sci. 2018;63:2864–2873. doi: 10.1007/s10620-018-5222-1. - DOI - PMC - PubMed
    1. Lurienne L., Bandinelli P.A., Galvain T., Coursel C.A., Oneto C., Feuerstadt P. Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: A US population survey. J. Patient-Rep. Outcomes. 2020;4:14. doi: 10.1186/s41687-020-0179-1. - DOI - PMC - PubMed
    1. Lessa F.C., Mu Y., Bamberg W.M., Beldavs Z.G., Dumyati G.K., Dunn J.R., Farley M.M., Holzbauer S.M., Meek J.I., Phipps E.C., et al. Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 2015;372:825–834. doi: 10.1056/NEJMoa1408913. - DOI - PMC - PubMed

Grants and funding

This research received no external funding.

LinkOut - more resources